Navigation Links
OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
Date:10/30/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 30, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2013 financial results will be released on Thursday, November 7, 2013, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results and will address frequently asked questions from investors.

"For this quarter's call, we are evaluating a new format in order to address questions submitted via our website and other channels. The discussion will include recent inquiries regarding the prostate cancer market landscape and our clinical development program," stated Scott Cormack, President and CEO of OncoGenex. "While we remain blinded to the SYNERGY and Borealis-1 data, we will review the estimated timelines, which remain unchanged from those disclosed in our quarterly report on Form 10-Q for the second quarter of 2013."  

Questions can be submitted via email to investor-relations@oncogenex.com. Those received before noon Pacific/3:00 p.m. Eastern on Thursday, Nov. 7, will be considered for the discussion.

  • To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days. You can also monitor key inf
    '/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
2. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
5. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
6. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
8. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
9. Hanger Reports Third Quarter 2013 Results
10. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
11. Questcor Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively ... June 8 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... ) today announced results from a meta-analysis of cardiovascular (CV) ... with BYETTA(R) (exenatide) injection use compared to a pooled comparator ...
... Dose Optimization of Pre-Clinical Otelixizumab Surrogate , ... a biopharmaceutical company engaged in the discovery and ... presented results from a pre-clinical dose-optimization study conducted ... monoclonal antibody, otelixizumab, at the 69th Scientific Sessions ...
Cached Medicine Technology:Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 2Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 3Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 4Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 5Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 6Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 3
(Date:7/31/2015)... and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. ... , Glancing out of the window, he recalled that his equipment was set up ... Street tower, he jumped out of bed. , The photo speaks for itself. Chatfield ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair transplant ... they are the latest recipients of the Center of Clinical Excellence for ARTAS ... worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration is ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. ... and post-acute care providers understand the benefits of using medication management technologies ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... Practice, Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce ... in a mobile application format available on iPhones, iPads, and Android smartphones ...
(Date:7/31/2015)... ... July 31, 2015 , ... “ Crack’em ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... make less mess while cooking. , Cooking can be a very messy experience, especially ...
Breaking Medicine News(10 mins):Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Make Less Mess while Cooking with Crack’em 2
... Hair with MilkSAN CLEMENTE, Calif., May 4 Maintaining strong, ... including Latinas. So when a new product comes on ... hair, many ladies jump on the bandwagon. The beauty ... more on hair care products than other Americans, according to ...
... Quality, for Company,s Medical DevicesPITTSBURGH, May 4 ... ), manufacturers of noninvasive medical evaluation equipment used ... other disorders, said today that it has earned ... and services.Nystagmography is the recording and measurement of ...
... new safety regulations, , , MONDAY, May 4 (HealthDay News) -- ... a mother. , Last March, her 2-year-old son and ... dressed in the bathroom. , Stevenson heard a crash. She ... lying on top of her daughter. Her son, Michael, was ...
... team of researchers at The National Cancer Center Hospital in ... lung cancer resection surgery between 2000 and 2006. The study ... of Thoracic Oncology , the official journal of the International ... his team found that after classifying patients based on the ...
... Others Question the Continuing Use of Mercury , WASHINGTON, ... Consumers for Dental Choice and the Mercury Policy Project, ... DHR ) corporation to transition out of manufacturing mercury ... Hotel in Washington D.C. this Tuesday, May 5 at ...
... The medical director for the Los Angeles Jewish ... in the western United States, today shared the Home,s ... for and precautions to take as fear of swine ... are very similar to that of the flu bugs ...
Cached Medicine News:Health News:Better Hair Days With Milk 2Health News:Better Hair Days With Milk 3Health News:Neuro Kinetics Earns ISO 13485 Certification 2Health News:More Kids Being Hurt by Falling Furniture 2Health News:More Kids Being Hurt by Falling Furniture 3Health News:Shareholders Challenge Danaher/Kerr to Phase Out Mercury Tooth Fillings 2Health News:Medical Director of Renowned Los Angeles Jewish Home Offers Advice to Seniors on Avoiding Swine Flu 2
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
PxE thermal Cycler. 0.2ml, 96 well block holds 96 tubes or 1 x 96 well plate. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User f...
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Medicine Products: